Video

Dr. Richard Harris on Advancements on the Horizon in Prostate Cancer

Richard Harris, MD, of UroPartners, says there are many exciting advancements currently happening in the field of prostate cancer. Harris shared his insights during an interview with OncLive at the 2016 LUGPA Annual Meeting.

Richard Harris, MD, of UroPartners, says there are many exciting advancements currently happening in the field of prostate cancer. Harris shared his thoughts during an interview with OncLive at the 2016 LUGPA Annual Meeting.

With regard to early diagnosis, genomic markers can help establish how aggressive a biopsy is and give urologists guidance on whether patients should be placed under active surveillance or treated.

Additionally, many new therapies are in clinical development for advanced prostate cancer. In this space, many clinical trials are looking at PARP inhibitors, which have a very bright future as far as helping manage certain forms of prostate cancer, Harris says.

Related Videos
Arndt Vogel, MD
Suresh S. Ramalingam, MD, FACP, FASCO, professor, Department of Hematology and Medical Oncology, Roberto C. Goizueta Distinguished Chair for Cancer Research, Emory University School of Medicine, executive director, Winship Cancer Institute of Emory University, associate vice president, cancer, Woodruff Health Sciences Center
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Stephen J. Freedland, MD
Ben Levy, MD, and Yan Leyfman, MD
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Timothy Yap, MBBS, PhD, FRCP
Timothy Yap, MBBS, PhD, FRCP